Search

Displaying results 1731 - 1740 of 10000 in total
  1. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.

  2. Drug

    (+)-menthol

    go.drugbank.com/drugs/DB11344
    Approved

    Mixtures: Ay Bendito - Pain Relief, Ay Bendito - Thermoactive
  3. Drug

    Corticotropin

    go.drugbank.com/drugs/DB01285
    ApprovedInvestigationalVet approved

    Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

  5. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Lithium citrate

    go.drugbank.com/drugs/DB14507
    ApprovedInvestigational

  7. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  9. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    can produce a broad adaptative and innate immune cell inhibitory activity. … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.